SlateStone Wealth LLC Has $4.03 Million Holdings in Johnson & Johnson (NYSE:JNJ)

SlateStone Wealth LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 164.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,743 shares of the company’s stock after acquiring an additional 14,142 shares during the period. Johnson & Johnson accounts for 0.9% of SlateStone Wealth LLC’s holdings, making the stock its 23rd largest position. SlateStone Wealth LLC’s holdings in Johnson & Johnson were worth $4,031,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the stock. Norges Bank acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $4,172,929,000. BlackRock Inc. raised its position in shares of Johnson & Johnson by 2.6% in the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after buying an additional 4,982,885 shares in the last quarter. GQG Partners LLC raised its position in shares of Johnson & Johnson by 1,109.4% in the fourth quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after buying an additional 3,627,424 shares in the last quarter. State Street Corp raised its position in shares of Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after buying an additional 2,492,359 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. raised its position in shares of Johnson & Johnson by 5,036.2% in the first quarter. Vaughan Nelson Investment Management L.P. now owns 1,227,558 shares of the company’s stock valued at $217,560,000 after buying an additional 1,203,658 shares in the last quarter. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JNJ. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating for the company. UBS Group lowered their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Finally, SVB Leerink lowered their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $171.79 on Friday. The firm’s fifty day moving average price is $175.41 and its two-hundred day moving average price is $174.52. The stock has a market cap of $451.67 billion, a PE ratio of 25.01, a PEG ratio of 3.29 and a beta of 0.59. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter in the previous year, the firm posted $2.48 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. On average, equities analysts expect that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio is 65.79%.

Insider Buying and Selling

In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.